Available and emerging treatments for parkinson's disease: A review

Drug Design, Development and Therapy

Volumn 5, Issue , 2011, Pages 241-254

  Hickey, Patrick ^a   Stacy, Mark ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenosine A2A antagonists; Deep brain stimulation; Gene therapy; Levodopa; Motor fluctuations; Parkinson's disease

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOVIRUS VECTOR; AMANTADINE; ANTIPARKINSON AGENT; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ISTRADEFYLLINE; LEVODOPA; LEVODOPA METHYL ESTER; MONOAMINE OXIDASE B INHIBITOR; NEURITE PROMOTING FACTOR; NEURTURIN; PLACEBO; PRAMIPEXOLE; PRELADENANT; PROSAVIN; RASAGILINE; ROPINIROLE; SAFINAMIDE; TOLCAPONE; UNCLASSIFIED DRUG; VIPADENANT;

AMINO ACID DECARBOXYLASE GENE; AREA UNDER THE CURVE; BRAIN DEPTH STIMULATION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSKINESIA; DYSTONIA; EDEMA; GENE; GENE THERAPY; GLUTAMIC ACID DECARBOXYLASE GENE; HALLUCINATION; HUMAN; IMPULSE CONTROL DISORDER; LOW DRUG DOSE; MOTOR DYSFUNCTION; NANOTECHNOLOGY; NONHUMAN; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; VIRAL GENE DELIVERY SYSTEM; ANIMAL; METABOLISM; METHODOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; GENE THERAPY; HUMANS; PARKINSON DISEASE;

EID: 80053898301     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S11836     Document Type: Review

References (189)

1. Stacy M. Medical treatment of Parkinson disease. Neurol Clin. 2009; 27(3):605-631.
2. Tanner CM, Ross GW, Jewell SA, et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009; 66(9):1106-1113.
3. US Census Bureau. US interim projections by age, sex, race, and hispanic origin: 2000-2050. Available from: http://www.census.gov/population/ www/projections/usinterimproj. Accessed March 18, 2004.
4. Cotzias GC, Papavasiliou PS, Gellene R. Modif ication of Parkinsonism-chronic treatment with L-dopa. N Engl J Med. 1969;280(7):337-345.
5. Lang AE, Lozano AM. title typecontributorParkinson's disease. First of two parts. N Engl J Med. 1998;339(15):1044-1053.
6. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2001;8(2):101-108.
7. Fahn S, Oakes D, Shoulson I, et al; for the Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-2508.
8. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol. 2000;47(Suppl 1):2-11.
9. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology. 1991;41(2 Pt 1):168-173.
10. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55(3):259-272.
11. Jellinger KA. Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl. 1999;56:1-29.
12. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci. 1984;4(11):2866-2876.
13. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41(1):1-24.
14. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopaminetreated rats. Brain Res. 1990;525(1):36-44.
15. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1-27.
16. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM. Realtime decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem. 2003;87(5): 1284-1295.
17. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677-687.
18. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med. 2008;359(23):2468-2476.
19. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994;44(5):913-919.
20. Nutt JG. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 2000;55:(11 Suppl 4):S33-S37.
21. De la Fuente-Fernández R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain. 2004;127 (Pt 12):2747-2754.
22. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol. 2000;47(4 Suppl 1):S167-S176.
23. Nutt JG, Carter JH, Lea ES, Woodward WR. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord. 1997;12(3):285-292.
24. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005;62(6): 905-910.
25. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord. 2007;22(8):1145-1149.
26. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 1998;13(2):234-241.
27. Rascol O, Brooks DJ, Korczyn AD, de Deyn PP, Clarke CE, Lang AE; For the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484-1491.
28. Olanow CW. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med. 2004;55:41-60.
29. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18-27.
30. Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord. 2005;20(3):306-314.
31. Suzuki K, Nakazato H, Matsui H, et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer. 2003;98(7):1411-1416.
32. Tanaka Y, Sasaki M, Shiina H, et al. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(2):238-244.
33. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975;25(12): 1144-1148.
34. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain. 1984;107 (Pt 2):487-506.
35. Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol. 1993;45(2): 117-122.
36. Sage JI, Schuh L, Heikkila RE, Duvoisin RC. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Clin Neuropharmacol. 1988;11(1):36-44.
37. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64(2):216-223.
38. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand. 2001;104(6):343-348.
39. Devos D; For the French DUODOPA Study Group. Patient profile, indications, eff icacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord. 2009;24(7):993-1000.
40. Nyholm D. Pharmacokinetics of levodopa/carbidopa infusion with and without oral catechol-O-methyl transferase (COMT) inhibitors (DuoCOMT). Available from: http://clinicaltrials.gov/ct2/show/ NCT00906828. Accessed December 2010.
41. Pekkonen E. Duodenal levodopa infusion, quality of life and autonomic nervous system in Parkinson's disease. Available from: http:// clinicaltrials.gov/ct2/show/NCT00914134. Accessed December 2010.
42. Lundqvist C, Beiske A. Continuous delivery of levodopa in patients with advanced idiopathic Parkinsons disease-cost-benefit. Available from: http://clinicaltrials.gov/ct2/show/NCT00272688. Accessed December 2010.
43. Nyholm D. Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics (DYSK-PD-2007). Available from: http://clinicaltrials.gov/ct2/show/NCT00888186. Accessed December 2010.
44. Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology. 1988;38(3):419-421.
45. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology. 1996;46(4):1051-1054.
46. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2003;2(2):107-116.
47. Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil. 2006;18(5): 369-375.
48. Steiger MJ, Stocchi F, Carta A, et al. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off " periods in Parkinson's disease. Clin Neuropharmacol. 1991;14(3):241-244.
49. Stocchi F, Fabbri L, Vecsei L, Krygowska-Wajs A, Monici Preti PA, Ruggieri SA. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol. 2007;30(1):18-24.
50. Stocchi F, Zappia M, Dall'Armi V, Kulisevsky J, Lamberti P, Obeso JA; For the Melevodopa Plus Carbidopa Study Group. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord. 2010; 25(12):1881-1887.
51. Chen D. An exploratory study of XP21279 (with Lodosyn®) and Sinemet® in Parkinson's disease subjects. Available from: http:// clinicaltrials.gov/ct2/show/NCT00914602. Accessed December 2010.
52. XenoPort. Product candidates, XP21279. Available from: http://www. xenoport.com/product/xp21279.htm. Accessed December 2010.
53. Hsu A, Verhagen Metman L, Ellenbogen A, et al. Comparison of IPX066, a novel extended-release oral carbidopa-levodopa formulation, to immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease. Am Acad Neurol. 2010;74(Suppl 2):A350.
54. Impax Study Director. A study to evaluate the safety and efficacy of IPX066 in subjects with Parkinson's disease (APEX-PD). Available from: http://clinicaltrials.gov/ct2/show/NCT00880620. Accessed December 2010.
55. Ferré S, O'Connor WT, Fuxe K, Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci. 1993;13(12):5402-5406.
56. Svenningsson P, Le Moine C, Aubert I, Burbaud P, Fredholm BB, Bloch B. Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J Comp Neurol. 1998;399(2):229-240.
57. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997;20(10):482-487.
58. Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology. 2003;61(11 Suppl 6):S44-S48.
59. Fenu S, Pinna A, Ongini E, Morelli M. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol. 1997;321(2):143-147.
60. Rose S, Ramsay Croft N, Jenner P. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res. 2007;1133(1):110-114.
61. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998;43(4):507-513.
62. Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J Neurochem. 2003;84(6):1398-1410.
63. Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000;162(2):321-327.
64. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology. 2003; 61(3):293-296.
65. Hauser RA, Hubble JP, Truong DD; For the Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61(3):297-303.
66. Lewitt PA, Guttman M, Tetrud JW, et al; For the 6002-US-005 Study Group. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off " time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63(3):295-302.
67. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008; 70(23):2233-2240.
68. Hauser RA, Shulman LM, Trugman JM, et al; For the Istradefylline 6002-US-013 Study Group. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008;23(15):2177-2185.
69. Guttman M. Eff icacy of istradefylline in Parkinson's disease patients treated with levodopa with motor response complications: primary efficacy results of the KW-6002 US-018 study. Mov Disord. 2006;21(Suppl 15):S585.
70. ClinicalTrials.gov. KW-6002 to treat Parkinson's disease. NCT00006337. Available from: http://clinicaltrials.gov/ct2/show/NCT00006337. Accessed December 2010.
71. Vernalis. 2nd generation A2A antagonist. Available from: http:// www.vernalis.com/development/cns/2nd-generation-a2a-antagonist#. Accessed December 2010.
72. ClinicalTrials.gov. A phase 2, 12-week, double-blind, dose-finding, placebo-controlled study to assess the efficacy and safety of a range of SCH 420814 doses in subjects with moderate to severe Parkinson's disease experiencing motor fluctuations and dyskinesias. Available from: http:// clinicaltrials.gov/ct2/show/NCT00406029. Accessed December 2010.
73. Hauser RA, Pourcher E, Micheli F, et al. Efficacy of preladenant, a novel A2A antagonist, as an adjunct to levodopa for the treatment of Parkinson's disease. Presented at Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movements Disorders, Paris, France (7-11 Jun 2009). Abstract Tu-185.
74. Huyck SB, Wolski K, Cantillon M. Impact of A2A receptor antagonist preladenant on dyskinesia in moderate to severe Parkinson's disease: post hoc analysis of dose-finding study. Presented at Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movements Disorders, Paris, France (7-11 Jun 2009). Abstract Tu-187.
75. Schering-Plough Research Institute. A placebo-and active-controlled study of preladenant in early Parkinson's disease (study P05664 AM2). Available from: http://clinicaltrials.gov/ct2/show/NCT01155479. Accessed December 2010.
76. Schering-Plough Research Institute. A placebo-and active controlled study of preladenant in subjects with moderate to severe Parkinson's disease (study P04938 AM2). Available from: http://clinicaltrials.gov/ ct2/show/NCT01155466. Accessed December 2010.
77. Synosia Therapeutics. Pipeline. Available from: http://www.synosia. com/pipeline.aspx. Accessed December 2010.
78. Sigma-Tau. Research development stages. Available from: http://www. sigma-tau.it/eng/fasidisviluppo.asp. Accessed December 2010.
79. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20): 2674-2679.
80. Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol. 2001;50(1):56-63.
81. Tan EK, Tan C, Fook-Chong SM, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci. 2003;216(1):163-167.
82. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord. 2007;22(15):2242-2248.
83. Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001;21(10):RC143.
84. Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem. 2002;80(2):262-270.
85. Pierri M, Vaudano E, Sager T, Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology. 2005;48(4):517-524.
86. Jenner P, Mori A, Hauser RA, Morelli M, Fredholm BB, Chen JF. Adenosine, adenosine A2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord. 2009;15(6):406-413.
87. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol. 2004;187(2):455-459.
88. Kupsch A, Sautter J, Götz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm. 2001;108(8-9):985-1009.
89. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004; 61(4):561-566.
90. Olanow CW, Rascol O, Hauser RA, et al; For the ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13): 1268-1278.
91. Kieburtz K. ADAGIO misses a beat? Lancet Neurol. 2009;8(12): 1081-1082.
92. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology. 2010;74(14): 1143-1148.
93. Marzo A, Dal Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of saf inamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004; 50(1):77-85.
94. Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67 (7 Suppl 2):S18-S23.
95. Stocchi F, Arnold G, Onofrj M, et al; For the Safinamide Parkinson's Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63(4):746-748.
96. Borgohain R, Szasz J, Bhatt M. Efficacy and safety of safinamide in patients with Parkinson's disease experiencing motor fluctuations: results of a 6-month phase III, randomized, double-blind, placebo-controlled study. 2009. Available from: http://www. movementdisorders.org/congress/congress09/late_breaking_ abstracts.pdf. Accessed December 2010.
97. Willmer J. Safinamide in levodopa induced dyskinesia in Parkinson's disease subjects (safinamide-LID). Available from: http://clinicaltrials. gov/ct2/show/NCT01113320. Accessed December 2010.
98. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2010;11(13):2261-2268.
99. Stacy M, Galbreath A. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Clin Neuropharmacol. 2008;31(1):51-56.
100. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22(16): 2409-2417.
101. Holloway R, Marek K, Biglan K, et al; For the Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563-570.
102. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287(13):1653-1661.
103. Whone AL, Watts RL, Stoessl AJ, et al; For the REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93-101.
104. Schapira AH, Albrecht S, Barone P, et al. Immediate vs delayedstart pramipexole in early Parkinson's disease: the PROUD study. Parkinsonism Relat Disord. 2009;15(Suppl 2):S81.
105. Schapira AH, Albrecht S, Barone P, et al. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord. 2010;25(11):1627-1632.
106. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L; for the Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24(10):2883-2895.
107. Pahwa R, Stacy MA, Factor SA, et al; For the EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007; 68(14):1108-1115.
108. Hersh BP, Earl NL, Hauser RA, Stacy M. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. Mov Disord. 2010;25(7):927-931.
109. Hauser RA, Schapira AH, Rascol O, et al. Randomized, doubleblind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord. 2010;25(15): 2542-2549.
110. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology. 2003;61(3):422-423.
111. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969-973.
112. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006; 67(7):1254-1257.
113. Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord. 2009; 24(11):1561-1570.
114. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595.
115. Thomas A, Bonanni L, Gambi F, di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400-404.
116. Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010;68(6):963-968.
117. Weintraub D. Naltrexone for impulse control disorders in Parkinson's disease. Available from: http://clinicaltrials.gov/ct2/show/ NCT01052831. Accessed December 2010.
118. Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci. 2010;1184:154-172.
119. Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol. 2009;88(4):272-285.
120. Staples M. Microchips and controlled-release drug reservoirs. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(4):400-417.
121. Linazasoro G; For the Nanotechnologies for Neurodegenerative Diseases Study Group of the Basque Country (NANEDIS). Potential applications of nanotechnologies to Parkinson's disease therapy. Parkinsonism Relat Disord. 2008;14(5):383-392.
122. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990; 249(4975):1436-1438.
123. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord. 1991;6(4):288-292.
124. Benazzouz A, Gross C, Féger J, Boraud T, Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic highfrequency stimulation in MPTP-treated monkeys. Eur J Neurosci. 1993;5(4):382-389.
125. Wichmann T, Bergman H, DeLong MR. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol. 1994;72(2):521-530.
126. Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano AM, Lang AE. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg. 2003;99(3):489-495.
127. Weaver FM, Follett K, Stern M, et al; For the CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73.
128. Follett KA, Weaver FM, Stern M, et al; For the CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010;362(22):2077-2091.
129. Mazzone P, Lozano A, Stanzione P, et al. Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson's disease. Neuroreport. 2005;16(17):1877-1881.
130. Plaha P, Gill SS. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. Neuroreport. 2005;16(17): 1883-1887.
131. Moro E, Hamani C, Poon YY, et al. Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain. 2010;133 (Pt 1):215-224.
132. Ferraye MU, Debû B, Fraix V, et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain. 2010;133(Pt 1):205-214.
133. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol. 2009;8(1):67-81.
134. Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg. 1996;84(2): 203-214.
135. Meissner W, Leblois A, Hansel D, et al. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain. 2005;128(Pt 10):2372-2382.
136. Welter ML, Houeto JL, Bonnet AM, et al. Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients. Arch Neurol. 2004;61(1):89-96.
137. Xia R, Berger F, Piallat B, Benabid AL. Alteration of hormone and neurotransmitter production in cultured cells by high and low frequency electrical stimulation. Acta Neurochir (Wien). 2007;149(1): 67-73.
138. Harnack D, Meissner W, Jira JA, Winter C, Morgenstern R, Kupsch A. Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism. Exp Neurol. 2008;210(1): 257-260.
139. Maesawa S, Kaneoke Y, Kajita Y, et al. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. J Neurosurg. 2004;100(4): 679-687.
140. Temel Y, Visser-Vandewalle V, Kaplan S, et al. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res. 2006;1120(1):100-105.
141. Wallace BA, Ashkan K, Heise CE, et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain. 2007;130 (Pt 8):2129-2145.
142. Spieles-Engemann AL, Behbehani MM, Collier TJ, et al. Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol Dis. 2010;39(1): 105-115.
143. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol. 1994;72(2):507-520.
144. Crossman AR, Mitchell IJ, Sambrook MA. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology. 1985;24(6):587-591.
145. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994;14(5): 783-801.
146. Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345(13):956-963.
147. Charles PD, van Blercom N, Krack P, et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology. 2002; 59(6):932-934.
148. Deuschl G, Schade-Brittinger C, Krack P, et al; For the German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.
149. Volkmann J. Deep brain stimulation for the treatment of Parkinson's disease. J Clin Neurophysiol. 2004;21(1):6-17.
150. Morgante L, Morgante F, Moro E, et al. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord. 2007;13(8):528-531.
151. Espay AJ, Vaughan JE, Marras C, Fowler R, Eckman MH. Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: a decision analysis. Mov Disord. 2010;25(10): 1456-1463.
152. Deuschl G; For the German Parkinson Study Group (GPS). Controlled trial of deep brain stimulation in early patients with Parkinson's disease. Available from: http://clinicaltrials.gov/ct2/show/NCT00354133. Accessed December 2010.
153. Charles PD. Deep brain stimulation (DBS) for early stage Parkinson's disease (PD). Available from: http://clinicaltrials.gov/ct2/show/ NCT00282152. Accessed December 2010.
154. Keeler CE. Gene therapy. J Hered. 1947;38(10):294-298.
155. Morrow JF. The prospects for gene therapy in humans. Ann N Y Acad Sci. 1976;265:13-21.
156. Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-120.
157. Bankiewicz KS, Forsayeth J, Eberling JL, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther. 2006;14(4):564-570.
158. Shen Y, Muramatsu S, Ikeguchi K, et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther. 2000;11(11): 1509-1519.
159. Muramatsu S, Fujimoto K, Ikeguchi K, et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopaminesynthesizing enzymes. Hum Gene Ther. 2002;13(3):345-354.
160. Jarraya B, Boulet S, Ralph GS, et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med. 2009;1(2):2ra4.
161. Oxford BioMedica. Oxford BioMedica announces two-year phase I/II results of ProSavin® in Parkinson's disease-6/14/2010. Available from: http://www.oxfordbiomedica.co.uk/page.asp? pageid=59&newsid=259. Accessed December 2010.
162. Palfi S. Phase I/II study of the safety, efficacy and dose evaluation of ProSavin for the treatment of bilateral idiopathic Parkinson's disease. Available from: http://clinicaltrials.gov/ct2/show/NCT00627588. Accessed December 2010.
163. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convectionenhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000;164(1):2-14.
164. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70(21):1980-1983.
165. Muramatsu S, Fujimoto K, Kato S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther. 2010;18(9):1731-1735.
166. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain. 2002;125(Pt 9):2058-2066.
167. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci. 2000; 23(10 Suppl):S109-S115.
168. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 1998;50(5 Suppl 5):S17-S25.
169. Carlsson T, Winkler C, Burger C, et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain. 2005;128(Pt 3):559-569.
170. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007; 369(9579):2097-2105.
171. Stoessl AJ. Gene therapy for Parkinson's disease: early data. Lancet. 2007;369(9579):2056-2058.
172. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004;291(3): 358-364.
173. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260(5111):1130-1132.
174. Nutt JG, Burchiel KJ, Comella CL, et al; For the ICV GDNF Study Group. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60(1):69-73.
175. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 1999;46(3): 419-424.
176. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAA V-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci. 2000; 20(12):4686-4700.
177. Wang L, Muramatsu S, Lu Y, et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther. 2002;9(6):381-389.
178. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000;290(5492):767-773.
179. Lo Bianco C, Déglon N, Pralong W, Aebischer P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol Dis. 2004;17(2): 283-289.
180. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589-595.
181. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol. 2005;57(2): 298-302.
182. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease [Erratum in: Ann Neurol. 2006;60(6):747]. Ann Neurol. 2006;59(3):459-466.
183. Gasmi M, Herzog CD, Brandon EP, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther. 2007; 15(1):62-68.
184. Gasmi M, Brandon EP, Herzog CD, et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007;27(1):67-76.
185. Kordower JH, Herzog CD, Dass B, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006;60(6):706-715.
186. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008;7(5): 400-408.
187. Siffert J. Double-blind, multicenter, sham surgery controlled study of CERE-120 in subjects with idiopathic Parkinson's disease. Available from: http://clinicaltrials.gov/ct2/show/NCT00400634. Accessed-December 2010.
188. Klejbor I, Stachowiak EK, Bharali DJ, et al. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology. J Neurosci Methods. 2007;165(2):230-243.
189. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones; 1817.